AVEO Oncology Announces Oral Presentation of 'TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced RCC' at ASCO GU 2019